A study of vitiligo in type 2 diabetic patients

Raveendra, Leena; Hemavathi, Rekha N; Rajgopal, Sushma

doi:10.4103/ijd.ijd_360_16

Cited by 13 publications

(12 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, no significant increase was found in the prevalence of insulin resistance or metabolic syndrome in their study [30]. Increased prevalence of vitiligo in type 2 diabetes patients has also been seen in some studies [31,32].…”

Section: Clinical Outcomesmentioning

confidence: 74%

Vitiligo: The Association With Metabolic Syndrome and the Role of Simvastatin as an Immunomodulator

Verma¹,

Hussain²,

Namiq³

et al. 2021

Cureus

View full text Add to dashboard Cite

Vitiligo is an autoimmune condition primarily affecting the skin where there is destruction of melanocytes characterized by pinkish-white patches on the skin. It is associated with other autoimmune diseases such as thyroid disease, rheumatoid arthritis, diabetes mellitus, and metabolic syndrome. Metabolic syndrome is a constellation of disorders including insulin resistance, hypertension, dyslipidemia, and obesity, and is considered a leading cause of cardiovascular morbidity. Simvastatin is a potent hypolipidemic drug that also possesses immunomodulating properties and is a common drug used in dyslipidemia and cardiovascular diseases. This study aimed to assess the association between vitiligo and metabolic syndrome and explore the immunomodulating properties of simvastatin for use in vitiligo. We reviewed various articles from PubMed, ResearchGate, and Google Scholar using different keywords and Medical Subject Headings and finalized 33 studies to be used in our review. The articles selected showed a positive association between vitiligo and metabolic syndrome or one of the component diseases of metabolic syndrome. The benefits of using simvastatin were also addressed by few articles attributing to its antioxidant and immunomodulating effect. However, there was no concrete explanation justifying the association between vitiligo and metabolic syndrome due to a limited number of studies and smaller sample size. Large-scale clinical trials should be conducted to evaluate the use of simvastatin as an immunomodulator in vitiligo to prevent possible metabolic complications.

show abstract

Section: Clinical Outcomesmentioning

confidence: 74%

Vitiligo: The Association With Metabolic Syndrome and the Role of Simvastatin as an Immunomodulator

Verma¹,

Hussain²,

Namiq³

et al. 2021

Cureus

View full text Add to dashboard Cite

show abstract

“…11 Similarly, vitiligo was observed in 12% of cases, and 6% in the age and sex-matched controls amidst one study examining 600 T2DM patients. 2,12,13 Recent studies likewise determined a 4.9% prevalence of vitiligo in T2DM individuals contrasting with 0.6% in the general population. 14…”

Section: Jo04022mentioning

confidence: 99%

Shining a Light on Vitiligo and Associated Comorbidities: What Is the Evidence?

Desai¹,

McCormick²,

Sodha³

et al. 2023

JDD

View full text Add to dashboard Cite

“…They concluded that the prevalence of diabetes in patients with vitiligo was statistically significant ( 77 , 78 ). Several studies have also found an increased prevalence of vitiligo in patients with type II diabetes ( 79 , 80 ).…”

Section: Abnormalities Of Glucose Metabolism Implicated In Vitiligomentioning

confidence: 99%

Immunometabolism in the pathogenesis of vitiligo

Lyu

Sun

2022

Front. Immunol.

View full text Add to dashboard Cite

Vitiligo is a common depigmenting skin disorder characterized by the selective loss of melanocytes. Autoimmunity, genetic, environmental, and biochemical etiology have been proposed in vitiligo pathogenesis. However, the exact molecular mechanisms of vitiligo development and progression are unclear, particularly for immunometabolism. Sporadic studies have suggested mitochondrial dysfunction, enhanced oxidative stress, and specific defects in other metabolic pathways can promote dysregulation of innate and adaptive immune responses in vitiligo. These abnormalities appear to be driven by genetic and epigenetic factors modulated by stochastic events. In addition, glucose and lipid abnormalities in metabolism have been associated with vitiligo. Specific skin cell populations are also involved in the critical role of dysregulation of metabolic pathways, including melanocytes, keratinocytes, and tissue-resident memory T cells in vitiligo pathogenesis. Novel therapeutic treatments are also raised based on the abnormalities of immunometabolism. This review summarizes the current knowledge on immunometabolism reprogramming in the pathogenesis of vitiligo and novel treatment options.

show abstract

A study of vitiligo in type 2 diabetic patients

Cited by 13 publications

References 12 publications

Vitiligo: The Association With Metabolic Syndrome and the Role of Simvastatin as an Immunomodulator

Vitiligo: The Association With Metabolic Syndrome and the Role of Simvastatin as an Immunomodulator

Shining a Light on Vitiligo and Associated Comorbidities: What Is the Evidence?

Immunometabolism in the pathogenesis of vitiligo

Contact Info

Product

Resources

About